It’s no secret the New England Patriots are thin at edge rusher. In fact, it’s probably one of their weakest positions on the roster right now. The issue became more apparent this week at Patriots ...

Good day, and welcome to the Tango Therapeutics conference call. [Operator Instructions] Please note, this call is being recorded. I'd now like to turn the call over to Liz Hickin, Vice President, ...

A shift in the way people think about and treat pancreatic cancer could be on the horizon based on positive results from the pivotal randomized phase 3 RASolute 302 trial comparing daraxonrasib to ...

An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients ...

Source: Aya Gold & Silver Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

- The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program - - 30 mg onvansertib + ...

At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously ...

Structured exercise program following adjuvant chemotherapy for colon cancer: A cost-utility analysis of the CHALLENGE trial. Circulating tumor DNA (ctDNA) clearance as an early indicator of sotorasib ...

A new drug for pancreatic cancer is showing promise in early testing. Daraxonrasib is a daily pill designed to block cancer signals linked to the RAS gene. It has now finished an early-stage clinical ...

Getting a depth module in Subnautica 2 increases your tadpole submarine's depth resistance and lets you explore further without having to worry about finding oxygen spots. However, you'll reach the ...

Newark Mayor Ras J. Baraka won a fourth term leading New Jersey’s largest city on Tuesday, based on unofficial results. Baraka received 70.3% of the votes cast with all 173 districts reporting, ...